Trial for J&J schizophrenia drug stopped early due to efficacy

|By:, SA News Editor

A phase III study for Johnson & Johnson's (JNJ) Paliperidone Palmitate 3-month formulation for schizophrenia has been stopped early due to the drug's effectiveness in delaying relapse when compared with a placebo.

The data is now set to be unblinded.

J&J unit Janssen, which developed the drug, plans to file for FDA approval of the treatment by the end of the year. (PR)